X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK Plc

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...
GSK

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
GSK Shingrex

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...
AstraZeneca

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...
GSK

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...
GSK Shingrex

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...
GSK

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
GSK

GSK Plc’s Nucala approved in China as a treatment for CRSwNP

GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
AstraZeneca

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...
GSK Plc

GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...
GSK

GSK Plc receives US FDA Breakthrough Therapy Designation

GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...
Broker Ratings

AstraZeneca plc 33.4% potential upside indicated by JP Morgan

AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 33.4% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..

GSK

GSK Plc Nucala COPD submission accepted by FDA

GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...
intravenous (IV) line

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
GSK plc

GSK plc RSV vaccine Arexvy approved in Japan

GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...
AstraZeneca

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...
AstraZeneca

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...
Haleon plc

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...
GSK Plc

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...
AZN

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

GSK Plc

GSK Plc reports strong growth in Specialty Medicines and R&D progress

GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns...
GSK

GSK plc Depemokimab applications accepted for review in China and Japan

GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
GSK Shingrex

GSK Plc Shingrix new prefilled syringe presentation accepted for review by EMA

GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe...
AstraZeneca

AstraZeneca Plc Datroway approved in the US for metastatic breast cancer

AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases...
GSK

GSK’s Jemperli gains EU approval for advanced endometrial cancer treatment

GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates...
GSK Shingrex

FDA accepts review of GSK Plc’s prefilled Shingrix syringe for vaccine approval

GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers...
GSK

GSK Plc’s ADC receives US FDA Breakthrough Therapy Designation

GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs...
GSK

GSK Plc’s Nucala approved in China as a treatment for CRSwNP

GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition...
AstraZeneca

AstraZeneca’s Tagrisso approved in the EU for patients with unresectable NSCLC

AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials...
GSK Plc

GSK Plc FIRST trial meetss primary endpoint in ovarian cancer

GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement...
GSK

GSK Plc receives US FDA Breakthrough Therapy Designation

GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development...
Broker Ratings

AstraZeneca plc 33.4% potential upside indicated by JP Morgan

GSK

GSK Plc Nucala COPD submission accepted by FDA

GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic...
intravenous (IV) line

AstraZeneca Plc Imfinzi approved in the US for limited-stage SCLC

AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
GSK plc

GSK plc RSV vaccine Arexvy approved in Japan

GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage...
AstraZeneca

AstraZeneca Plc expands US R&D and manufacturing footprint with $3.5b investment

AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint...
AstraZeneca

AstraZeneca Plc Tezspire meets primary endpoints in WAYPOINT trial

AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients...
Haleon plc

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights...
GSK Plc

GSK Plc confirms 2024 guidance; Q3 dividend of 15p declared

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...
AZN

AstraZeneca’s Wainzua recommended for approval in the UK

AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple